Bayer AG (BAYRY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
This study, listed as NCT07535112, aims to test a new Bayer drug called BAY 3771249 in people with advanced colorectal cancer that carries a KRAS G12D mutation. The goal is to see how safe the drug is, how well patients tolerate it, and whether it can slow or shrink tumors where current options are limited.
The trial tests BAY 3771249 as an oral drug on its own and combined with the infused cancer drug cetuximab. The intent is to block the KRAS G12D signal that drives tumor growth and to see if pairing it with an existing targeted therapy can further improve disease control.
The design is an early stage treatment trial with no placebo group, and all patients know what they receive. Doses rise step by step in a first phase, then the most promising dose is used in more patients to confirm safety and early signs of benefit.
The study opened in April 2026 when the first protocol was submitted and is currently recruiting patients. The latest update was filed on May 15, 2026, and both the primary and final completion dates are still in the future as Bayer gathers more data.
For investors, this update signals Bayer’s push into KRAS G12D, a target that rivals like Amgen and other biotech firms are also chasing. Any strong safety and response signals could support sentiment for Bayer’s oncology pipeline, though as a Phase 1 asset it remains high risk and several years from potential revenue.
The trial remains active and updated, and investors can find further details and ongoing changes on the ClinicalTrials portal.
To learn more about BAYRY’s potential, visit the Bayer AG drug pipeline page.